{"id":"https://openalex.org/W4296823104","doi":"https://doi.org/10.1158/2767-9764.crc-22-0172","title":"Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity","display_name":"Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity","publication_year":2022,"publication_date":"2022-09-23","ids":{"openalex":"https://openalex.org/W4296823104","doi":"https://doi.org/10.1158/2767-9764.crc-22-0172","pmid":"https://pubmed.ncbi.nlm.nih.gov/36506732","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9730833"},"language":"en","primary_location":{"id":"doi:10.1158/2767-9764.crc-22-0172","doi":"https://doi.org/10.1158/2767-9764.crc-22-0172","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-22-0172","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2767-9764.crc-22-0172","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000853381","display_name":"Mahesh Raj Nepal","orcid":"https://orcid.org/0000-0001-7259-2699","observed_orcids":["https://orcid.org/0000-0001-7259-2699"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mahesh R. Nepal","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067184440","display_name":"Hanieh Taheri","orcid":"https://orcid.org/0000-0003-3236-7870","observed_orcids":["https://orcid.org/0000-0003-3236-7870"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hanieh Taheri","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100421368","display_name":"Yang Li","orcid":"https://orcid.org/0000-0001-9055-2332","observed_orcids":["https://orcid.org/0000-0001-9055-2332"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yang Li","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":"https://orcid.org/0000-0001-9055-2332","affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101783607","display_name":"Zahra Talebi","orcid":"https://orcid.org/0000-0001-9166-5160","observed_orcids":["https://orcid.org/0000-0001-9166-5160"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zahra Talebi","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046631238","display_name":"Muhammad Erfan Uddin","orcid":"https://orcid.org/0000-0002-7160-0455","observed_orcids":["https://orcid.org/0000-0002-7160-0455"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Muhammad Erfan Uddin","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":"https://orcid.org/0000-0002-7160-0455","affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yan Jin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Jin","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044512737","display_name":"Duncan F. DiGiacomo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Duncan F. DiGiacomo","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068080699","display_name":"Alice A. Gibson","orcid":"https://orcid.org/0000-0001-5910-5067","observed_orcids":["https://orcid.org/0000-0001-5910-5067"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alice A. Gibson","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":"https://orcid.org/0000-0001-5910-5067","affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086903918","display_name":"Maryam B. Lustberg","orcid":"https://orcid.org/0000-0001-8559-5645","observed_orcids":["https://orcid.org/0000-0001-8559-5645"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]},{"id":"https://openalex.org/I4210165192","display_name":"Smilow Cancer Hospital","ror":"https://ror.org/05q3szf80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maryam B. Lustberg","raw_affiliation_strings":["3The Breast Center at Smilow Cancer Hospital at Yale, Yale School of Medicine, New Haven, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3The Breast Center at Smilow Cancer Hospital at Yale, Yale School of Medicine, New Haven, Connecticut","institution_ids":["https://openalex.org/I32971472","https://openalex.org/I4210165192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077955893","display_name":"Shuiying Hu","orcid":"https://orcid.org/0000-0002-9806-7734","observed_orcids":["https://orcid.org/0000-0002-9806-7734"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shuiying Hu","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":"https://orcid.org/0000-0002-9806-7734","affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"2Division of Outcomes and Translational Sciences, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065279964","display_name":"Alex Sparreboom","orcid":"https://orcid.org/0000-0003-2660-6644","observed_orcids":["https://orcid.org/0000-0003-2660-6644"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alex Sparreboom","raw_affiliation_strings":["1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio"],"raw_orcid":"https://orcid.org/0000-0003-2660-6644","affiliations":[{"raw_affiliation_string":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5065279964","https://openalex.org/A5077955893"],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":{"value":2550,"currency":"USD","value_usd":2550},"apc_paid":{"value":2550,"currency":"USD","value_usd":2550},"fwci":0.8365,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.72974248,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"2","issue":"11","first_page":"1334","last_page":"1343"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.5669000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.5669000148773193,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.4074999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.8220000267028809},{"id":"https://openalex.org/keywords/peripheral-neurotoxicity","display_name":"peripheral neurotoxicity","score":0.9549999833106995},{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":0.972000002861023},{"id":"https://openalex.org/keywords/oct2","display_name":"OCT2","score":0.9020000100135803},{"id":"https://openalex.org/keywords/dorsal-root-ganglion-neurons","display_name":"dorsal root ganglion neurons","score":0.9829999804496765},{"id":"https://openalex.org/keywords/drug-transport","display_name":"drug transport","score":0.47200000286102295},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.7509999871253967},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.625},{"id":"https://openalex.org/keywords/anticancer-drug-side-effects","display_name":"anticancer drug side effects","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.9636505842208862},{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.852387011051178},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7061033248901367},{"id":"https://openalex.org/C2910564767","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine Hydrochloride","level":4,"score":0.6740615367889404},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5446675419807434},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.5123366117477417},{"id":"https://openalex.org/C2779491297","wikidata":"https://www.wikidata.org/wiki/Q3338704","display_name":"Neurotoxicity","level":3,"score":0.507117748260498},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.46812310814857483},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3529778718948364},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.29141393303871155},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2531452775001526},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22403937578201294},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.17493408918380737},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1746959388256073},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.17260083556175232},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17023783922195435},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09611019492149353},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077150","descriptor_name":"Oxaliplatin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010523","descriptor_name":"Peripheral Nervous System Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D020258","descriptor_name":"Neurotoxicity Syndromes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/2767-9764.crc-22-0172","doi":"https://doi.org/10.1158/2767-9764.crc-22-0172","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-22-0172","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9730833","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9730833","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Res Commun","raw_type":"Text"},{"id":"pmid:36506732","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36506732","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research communications","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/2767-9764.crc-22-0172","doi":"https://doi.org/10.1158/2767-9764.crc-22-0172","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-22-0172","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1001886291","display_name":"Prevention of paclitaxel-induced peripheral neuropathy with nilotinib","funder_award_id":"R01CA238946","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1930221042","display_name":"(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics","funder_award_id":"R01CA215802","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000895941","display_name":"The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN","funder_award_id":"U24CA247648","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000905448","display_name":"Yale Clinical and Translational Science Award","funder_award_id":"UL1TR001863","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337472","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1873305365","https://openalex.org/W1910455479","https://openalex.org/W1970125541","https://openalex.org/W1971574764","https://openalex.org/W1993221666","https://openalex.org/W1997672693","https://openalex.org/W2002211622","https://openalex.org/W2005216778","https://openalex.org/W2027086950","https://openalex.org/W2033759020","https://openalex.org/W2047894869","https://openalex.org/W2049899770","https://openalex.org/W2052278699","https://openalex.org/W2053242178","https://openalex.org/W2057662279","https://openalex.org/W2087522889","https://openalex.org/W2108398230","https://openalex.org/W2109846148","https://openalex.org/W2118441791","https://openalex.org/W2129145601","https://openalex.org/W2161465647","https://openalex.org/W2162349483","https://openalex.org/W2299952886","https://openalex.org/W2552026614","https://openalex.org/W2637410905","https://openalex.org/W2774101517","https://openalex.org/W2783215140","https://openalex.org/W2887926439","https://openalex.org/W2894405759","https://openalex.org/W2896392523","https://openalex.org/W2912092571","https://openalex.org/W2939152062","https://openalex.org/W2946373148","https://openalex.org/W3015025259","https://openalex.org/W3019832371","https://openalex.org/W3029084204","https://openalex.org/W3043680095","https://openalex.org/W3045813318","https://openalex.org/W3047287983","https://openalex.org/W3096292701","https://openalex.org/W3132776754","https://openalex.org/W3186172665","https://openalex.org/W3212165740","https://openalex.org/W3217251942","https://openalex.org/W4245530369"],"related_works":["https://openalex.org/W4281729275","https://openalex.org/W3017295529","https://openalex.org/W3207717469","https://openalex.org/W4225673949","https://openalex.org/W3124126256","https://openalex.org/W7140296465","https://openalex.org/W4206919709","https://openalex.org/W2052278699","https://openalex.org/W3210338691","https://openalex.org/W4245530369"],"abstract_inverted_index":{"Oxaliplatin-induced":[0],"peripheral":[1],"neurotoxicity":[2],"(OIPN)":[3],"is":[4,16],"a":[5,118,145,175,235,306],"debilitating":[6],"side":[7,45],"effect":[8,46],"that":[9,15,51,131,255,294],"afflicts":[10],"approximately":[11],"90%":[12],"of":[13,21,99,103,111,117,126,138,151,160,191,198,219,266,274,289,297,316],"patients":[14,245],"initiated":[17],"by":[18,213,300],"OCT2-dependent":[19],"uptake":[20,195],"oxaliplatin":[22,199,267],"in":[23,42,73,83,123,144,171,183,200,204,207,244],"dorsal":[24],"root":[25],"ganglion":[26],"(DRG)":[27],"neurons.":[28,270],"The":[29,215],"antidepressant":[30],"drug":[31],"duloxetine":[32,52,100,132,157,256,277,301],"has":[33,53,257],"been":[34],"used":[35,59,95],"to":[36,63,66,96,163,174,178,309],"treat":[37],"OIPN,":[38,104],"although":[39],"its":[40,231],"usefulness":[41],"preventing":[43,242],"this":[44],"remains":[47],"unclear.":[48],"We":[49,129,253],"hypothesized":[50],"OCT2-inhibitory":[54,259],"properties":[55,218,260,288],"and":[56,82,91,108,113,149,153,168,196,206,261,286],"can":[57,262,302],"be":[58,303],"as":[60,234,305],"an":[61],"adjunct":[62],"oxaliplatin-based":[64,317],"regimens":[65],"prevent":[67],"OIPN.":[68],"Transport":[69],"studies":[70,239],"were":[71,94,209],"performed":[72],"cells":[74],"stably":[75],"transfected":[76],"with":[77,222,246,250,276],"mouse":[78,85],"or":[79],"human":[80],"OCT2":[81,106],"isolated":[84],"DRG":[86,164,269],"neurons":[87,165],"ex":[88,166],"vivo.":[89],"Wild-type":[90],"OCT2-deficient":[92,184],"mice":[93,173,275],"assess":[97],"effects":[98],"on":[101],"hallmarks":[102],"endogenous":[105],"biomarkers,":[107],"the":[109,114,135,179,188,194,223,283,314],"pharmacokinetics":[110,285],"oxaliplatin,":[112,143],"translational":[115],"feasibility":[116],"duloxetine-oxaliplatin":[119],"combination":[120],"was":[121],"evaluated":[122],"various":[124],"models":[125],"colorectal":[127],"cancer.":[128],"found":[130,254],"potently":[133],"inhibited":[134],"OCT2-mediated":[136,298],"transport":[137,299],"several":[139],"xenobiotic":[140],"substrates,":[141],"including":[142],"reversible,":[146],"concentration-dependent":[147],"manner,":[148],"independent":[150],"species":[152],"cell":[154,202],"context.":[155],"Furthermore,":[156],"restricted":[158],"access":[159],"these":[161],"substrates":[162],"vivo":[167,208],"prevented":[169,278],"OIPN":[170,243,279,311],"wild-type":[172],"degree":[176],"similar":[177],"complete":[180],"protection":[181],"observed":[182,216],"mice,":[185],"without":[186,280,312],"affecting":[187],"plasma":[189,284],"levels":[190],"oxaliplatin.":[192,251,290],"Importantly,":[193],"cytotoxicity":[197],"tumor":[201],"lines":[203],"vitro":[205],"not":[210],"negatively":[211],"influenced":[212],"duloxetine.":[214],"OCT2-targeting":[217],"duloxetine,":[220],"combined":[221],"potential":[224],"for":[225,230,238],"clinical":[226],"translation,":[227],"provide":[228],"support":[229],"further":[232],"exploration":[233],"therapeutic":[236],"candidate":[237],"aimed":[240],"at":[241],"cancer":[247],"requiring":[248],"treatment":[249],"Significance:":[252],"potent":[258],"diminish":[263],"excessive":[264],"accumulation":[265],"into":[268],"In":[271],"addition,":[272],"pretreatment":[273],"significantly":[281],"altering":[282],"antitumor":[287],"These":[291],"results":[292],"suggest":[293],"intentional":[295],"inhibition":[296],"employed":[304],"prevention":[307],"strategy":[308],"ameliorate":[310],"compromising":[313],"effectiveness":[315],"treatment.":[318]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-09-24T00:00:00"}